XM does not provide services to residents of the United States of America.
A
A

Abbott

Trade Ideas

Traders Sentiment

Technical Summary

Hourly

News

Abbott Receives CE Mark For Its Assert-IQ Insertable Cardiac Monitor, Expanding Availability Of Long-Term Monitoring For Irregular Heart Rhythms

BRIEF-Abbott Receives CE Mark For Its Assert-IQ Insertable Cardiac Monitor, Expanding Availability Of Long-Term Monitoring For Irregular Heart Rhythms March 25 (Reuters) - Abbott Laboratories ABT.N : ABBOTT RECEIVES CE MARK FOR ITS ASSERT-IQ INSERTABLE CARDIAC MONITOR, EXPANDING AVAILABILITY OF LONG-TERM MONITORING FOR IRREGULAR HEART RHYTHMS Sourc
A

S&P 500 top and bottom performing stocks at about 03:32 p.m. EDT

BUZZ - S&P 500 top and bottom performing stocks at about 03:32 p.m. EDT S&P 500 .SPX Top Performers Percent Change Tesla Inc TSLA.OQ +6.5% Alphabet Inc GOOGL.OQ +4.4% Match Group Inc MTCH.OQ +4.4% Adobe Inc ADBE.OQ +4.4% Alphabet Inc GOOG.OQ +4.3% Bottom Performers Percent Change Super Micro Computer Inc SMCI.OQ -5.8% International Paper Co IP.N -3
A
A
G
M
T
U

Reckitt slump offers a cue to slim down

BREAKINGVIEWS-Reckitt slump offers a cue to slim down The author is a Reuters Breakingviews columnist. The opinions expressed are her own. Updates to add graphic. By Aimee Donnellan LONDON, March 18 (Reuters Breakingviews) - Jeremy Darroch has a job on his hands. The former Sky CEO, soon to take over as chair of 33 billion pound ($41 billion) Reckitt Benckiser RKT.L , is inheriting a company whose shares have fallen nearly 25% in under a month – including a 15% slump on Friday after it lost a
A
B

U.S. STOCKS Emeren Group, Steel Dynamics, NYCB

BUZZ-U.S. STOCKS ON THE MOVE-Emeren Group, Steel Dynamics, NYCB Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's main stock ind0inflation figures could sully hopes of an early start to the Federal Reserve's rate-easing cycle.
A
A
C
G
M
S
U
U
U
B

Abbott falls after Reckitt unit hit with $60 mln payout in baby formula case

BUZZ-Abbott falls after Reckitt unit hit with $60 mln payout in baby formula case ** Shares of medical device maker Abbott Laboratories ABT.N fall 4.4% to $113.65 ** Enfamil baby formula maker Reckitt Benckiser RKT.L has been ordered to pay $60 million to the mother of a premature baby who died of an intestinal disease after being fed the formula *
A

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.